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Abstract A relationship has been reported between sub-optimal inhaler technique and control of asthma
symptoms. Randomised controlled trials and systematic reviews may fail to accurately represent this relationship,
byexcludingpatientswho areunable to correctlyusetherevieweddevices.Breath actuatedinhalers (BAIs) arereported
tobeeasier tousethanmetereddoseinhalers (MDIs).This studyuses alargeprimarycaremedicalrecorddatabase (DIN-
LINK) to examine the ‘real-life’ clinical effectiveness of a BAI vs. traditional MDIs. A comparison is made between the
quantity of asthma-related medication (b2 agonist, oral steroids and antibiotics) and healthcare resource use required
by children (0^12 years) and adults (13+ years) using either the BAI or an MDI over a 12-month period.Out of 5556
newasthma patientswhometthe inclusion criteria, 306 used a BAI and 5250 used a traditional MDI.Children and adults
using the BAIreceived fewer prescriptions for all threemedicationtypes thanthose using a traditional MDI (children: b2
agonists 18% P= 0.036, oral steroids88% Po0.05, antibiotics ^68% Po0.05 and adults: b2 agonists10.9% P= 0.179,
oral steroids 51.2% Po0.05, antibiotics 19.5% P= 0.276). All prescription results reached statistical significance, with
the exception of b2 agonist and antibiotic prescription numbers for adult patients.Children and adults using the BAI re-
quiredless GPconsultations for asthma (children30.3%,Po0.05 andadults22.9%,Po0.05) andless GPconsultations
for respiratory infections than those using a traditional MDI (children 35.2%, P-0.001 and adults 10.4%, P= 0.236).
Adults using the BAI required less outpatient appointments than adults using an MDI (43.7%, P= 0.166). All non-pre-
scriptionresourceresultsreached statistical significancewiththe exceptionof GPconsultations forrespiratoryinfections
and outpatient visits in the adult group. In conclusion, children and adults using the BAI appear to have better asthma
control than children and adults using an MDI as evidenced by fewer relief medication prescriptions and less healthcare
resource use.r2002 Elsevier Science Ltd.Allrights reserved.
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sINTRODUCTION
There are currently more than 5 million people in the
U.K. who are living with asthma and a large proportion
of these have disease that is inadequately controlled
(1^3).Thispersisting asthmamorbidity is re£ectedinhigh
levels of healthcare utilisation, with many people requir-Received1March 2002, accepted in revised form 3 July 2002.
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AB25 2AY,U.K.Fax: +441224 550683; E-mail: d.price@abdn.ac.uking urgent primary and secondary care attendance (4).
Consequently, the total (indirect anddirect) cost of asth-
ma to the NHS amounts to approximately d2 billion per
year (5).
Guidelines (6^8) recommend regular anti-in£amma-
tory therapy for all but the mildest asthma, although
pragmatic surveys have found 50% or more of patients
do not adhere to recommended inhaled corticosteroid
(ICS) regimes and even those who do, frequently use
their inhalers incorrectly (9,10).
Themainstay of treatment for asthma is by the inhala-
tion of medication to the site of disease process in the
airways. A number of di¡erent inhaler delivery systems
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metred dose inhalers (MDIs), whichmay be propelled by
chloro£uorocarbon (CFC) or non-CFC propellants,
breath-activated MDIs and dry powder inhalers (DPIs).
In the past the majority of devices have been CFC-pro-
pelled MDIs, but environmental concerns over the ef-
fects of CFCs on the ozone layer and over relatively
poor drug delivery to the airways have led to the devel-
opment and wider use of other types of inhalers.These
include MDIs propelled by non-CFC hydro£uoroalkanes,
breath-actuated MDIs (BAIs) and a variety of DPI sys-
tems. These systems all have advantages and disadvan-
tages in terms of costs, ease of use and drug deposition
characteristics. The relative clinical and cost e¡ective-
ness of di¡erent systems in real-life everyday practice is
debated.There is some evidence that particular systems
may be appropriate for di¡erent patients (11). A delivery
system that is preferred and can be used e¡ectively by
the patientmay result in improved clinical and economic
outcomes. MDIs remain however the most frequently
prescribed devices in the U.K. and inmost countries.
Poor asthma control can be at least partly attributed
to non-adherence with medication (1, 12^14). However,
evenwhen patients are fully adherent to agreed ICSregi-
mens, lung deposition may be altered by patient charac-
teristics (including poor inhaler technique) and
characteristics of the inhaler device used (8,11,15^17). If
sub-optimal levels of ICS are received, this may result in
poor asthma controlwith increased symptoms, impaired
quality of life, excessive reliever medication use, hospita-
lisation, increaseduse of emergency services andeven in-
creasedmortality (4,18).
Attempts to rectify the problem of poor inhaler tech-
niquehavebeenmade through structuredasthma educa-
tion programmes (5,19), employment of trained asthma
nurses (4,19) and regular checks on inhaler technique
(19).These interventions have had varied success [5], with
the degree of success appearing to correlatewith the in-
tensity of the intervention (19).
Currently, the most widely used inhalers in many
countries are MDIs. Technique with MDIs has been
shown to be correct in only 21^64% (15,20,21) of patients
and drug delivery to the lungswith a traditionalMDI var-
ies from7^20% (22).Themajor problems foundwithMDI
use are: oral mucosal deposition of drug with associated
local side e¡ects; poor co-ordination betweenbreathing
and ¢ring and too fast an inspiration (23). Intensive in-
struction has been shown to improve performance
(21,24); however the bene¢t appears to be transitory,
especially in children (21).
However, a recent systematic review concluded that
MDIs are as clinically e¡ective as all other inhaler devices
(25^27). It has been commented that this review may
notrepresentreal-life (28^30).One criticism is that a ne-
cessary entry criterion for many of the included trials is
the ability to use MDIs correctly, thus selecting atypicaland unrepresentative patient cohorts and raising ques-
tions over generalisability of results (28,29). Such con-
trolled trials also do not provide pertinent information
regarding the education needs of people with asthma
(19).Consequently, the review does not consider indirect
costs of treatment failure and more intense education
associatedwith MDI use (28).
BAIs have similar appearance to traditional MDIs (31),
but being actuated by a slow inspiration, do not require
the press-and-breathe co-ordination needed for tradi-
tional MDI use (31). In several studies patients and nurses
have foundBAIs easier to use, easier to teach andprefer-
able to traditional MDIs (22,31^36). Studies report lower
error rates with BAIs compared to traditional MDIs (34)
and that BAI users often have better inhaler technique
(34,37,38).There is a lack of health economic evaluations
of the consequences of choosing di¡erent inhaler de-
vices.
Whilst randomised controlled trials (RCTs) and sys-
tematic reviewsprovide good evidence of clinical e⁄cacy
in trial settings they often exclude those patients using
inhalers incorrectlyor inadequately, which does not hap-
pen in‘real-life’ as all of these patients require treatment.
In recognition of this there is an increasingmove to sup-
plement e⁄cacy data with ‘real-life’ pragmatic trials and
observational data that focus on what happens in every-
day practice.
This study aimed to investigate whether there is any
evidence in a large prescribing and healthcare utilisation
database of ‘real-life’ greater clinical e¡ectiveness for
BAIs over traditional MDIs in line with the data on pa-
tient preference and inhaler technique, but in contrast
to that from the published systematic review (25^27).
METHODOLOGY
This study is a retrospective cross-sectional comparison
of medication and health resource usage in patients pre-
scribed inhaled corticosteroids either by a BAI (Easi-
Breathes) or a traditional MDI delivery system. The
study utilises an electronic U.K. primary care clinical
and prescribing database, with amount of rescue and re-
lief medication and respiratory-related primary and sec-
ondary care resource use as the main outcome
measures.
DIN-LINKDatabase
TheDIN-LINKdatabase contains in-depthmedical infor-
mation from approximately 210 GP practices in Great
Britain. In total, approximately 380 GPs and almost
900 000 live patients are represented by the database.
This medical information is screened to allow analysis of
only themost accurate and complete data (amounting to
100 practices for this particular analysis). Practices are
14 RESPIRATORYMEDICINEgeographically spread and comprise a range of sizes [39].
DIN-LINK has been used previously in similar published
reviews of prescribing practices in the U.K. (40).
DIN-LINK is limited to GP practices using the AAH
Meditel computer system and the data obtained is de-
pendent on the completeness of the information en-
tered. This means that numbers for hospital admissions
and outpatient appointmentsmay be under reported.
Patients
All patientswith a diagnosis of asthma and attending one
of the 100 DIN-LINKGP practices included in the study
were eligible for inclusion in the study if theymet the fol-
lowing criteria:
K Newly prescribed an ICS during the 21months from
July 1998 to March 2000 to avoid the in£uence of
previous therapy or disease course.
K Solely used either the same MDI or BAI for all the
inhaled asthma medication for a full 12-month period
in order to avoid contamination of outcomes for
patients receivingmore than one device.
K Received only the Easi-Breathes BAI device to avoid
distortion by the di¡ering attributes of individual
BAIs.
Study design
This was a retrospective cohort comparison study using
data from the DIN-LINK (Doctors Independent Net-
work) database (39) to test the a priori hypothesis that
improved asthma controlresulting from theprescription
BAIs would result in improvements in the various health
resource utilisation parameters reported above those
associated with prescription of MDIs. The study design
and analysis involved a steering group independent of
the study sponsors.
Medical records of patients meeting the inclusion cri-
teria were analysed to identify the asthma-relatedmedi-
cation and other clinical resources used by patients over
a period of 12 months (i.e. 12 months from the date of
their ¢rst inhaled steroidprescription).Patientswere ca-
tegorised into cohorts according to the device used for
ICS therapy. BAI patients were those who were com-
menced on the BAI (Easi-Breathes) as their ¢rst ICS
treatment, remaining on the BAI throughout the study
period.MDI patients were those who were commenced
on anMDI as their ¢rst ICS treatment, remaining on the
MDI throughout the study period.
The resultswere further categorised into children (0^
12) and adults (13+).BAIs are notroutinelyprescribed for
0^5 year olds (who aremost likely to beprescribeda tra-
ditional MDI plus spacer); therefore an additional sub-
group analysis was performed in order to check for bias.This additional analysis separated the results of younger
(0^5 years) and older (6^12 years) children.
Methods
Cohort comparability
Socio-economic status was examined using (ACORN)
the a classi¢cation of residential neighbourhoods socio-
economic groups (41). Average age and gender split were
comparedbetween the traditional MDI and BAI cohorts
to con¢rm demographic comparability. The average
number of ICS pu¡s per patient, per year was calculated
to con¢rm comparability of asthma severity.
Measuring asthma control
In order to measure the degree of asthma control ex-
perienced by the MDI and BAI cohorts, routinely re-
corded asthma-related prescribing and other relevant
resource usagewere compared.
Prescribing Medication information was reported in
mean number of prescriptions, per patient, per study
period (12 months). The following medication has been
included in the study:
K b2 agonist usage which has been used and
recommended as a measure of asthma control in
guidelines (8) as well as in other studies (42).
K Oral steroids courses were included as real-life
markers of signi¢cant asthma exacerbations as their
usage is recommended in acute exacerbations (8).
K Patients with uncontrolled asthma aremore prone to
being diagnosed with respiratory infections (43^45);
therefore antibiotic usage provides useful additional
information about asthma control.
Other resources The frequency with which a patient
needs to see their GP for asthma-related symptoms or
respiratory infections is considered a good indicator of
asthma control (4). Likewise, the frequency of requiring
referral for outpatient appointments or hospital admis-
sions is likely to correlate with the degree of control the
patient is experiencing (4). These resources have been
analysed and are reported as the mean number of con-
sultations/visits/admissions per patient/per year.
Statistical analyses
Statistical analyses were performed using statistical
package social services (SPSS) version 10.1. Sub-group
comparisonswereproducedby theuse of analysis of var-
iance (ANOVA) and the Students’t-test (two group com-
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In addition, 95% con¢dence intervals are provided for
continuous variables.
RESULTS
A total of 5556 eligible new patient records were identi-
¢ed (5250 using an MDI and 306 using the BAI (Easi-
Breathes). Children accounted for 1646 of the patients.
TheMDI and BAI cohorts are similar with respect to pa-
tient characteristics (Table 1). Children prescribed an
MDI are on average 4 years younger than children pre-
scribed the BAI as younger children (0^5 years) are unli-
kely to be prescribed breath-actuated MDIs (see
additional sub-group analysis).There are also more adult
women prescribed the BAI than adultmen.The relation-
ship trendbetween gender and asthma prevalence in the
present study agrees with literature on UK asthma pre-
valence (46). In children and young adults asthma ismore
prevalent in males, whereas the trend reverses to a fe-
malemajority in older adults.
The BAI and MDI cohorts are similar with regard to
socio-economic status (ACORN scores) (41) (Table 2).
The average number of prescribed ICS pu¡s per patient,
per year for the MDI and BAI cohorts is similar
(BAI=691.91pu¡s,MDI=661.20 pu¡s).TABLE 1. Patientcharacteristics (gender andmean age)
BAI MDI
Children
(0^12 years)
Adults
(13+years)
Children
(0^12 years)
Adults
(13+years)
n= 61 n= 245 n= 1585 n= 3665
%Male 49 40 58 43
Mean age
years
8.8 39.2 5.0 37.9
(95% CI) (8.21,9.40) (36.67,41.69) (4.82,5.13) (37.35,38.49)
TABLE 2. Socio-economic status (ACORN scores) (41)
Number (%)
ACORN score MDI BAI
A Thriving 963 (18.3) 72 (23.5)
B Expanding 697 (13.3) 50 (16.3)
C Rising 255 (4.9) 8 (2.6)
D Settling 1035 (19.7) 47 (15.4)
E Aspiring 499 (9.5) 40 (13.1)
F Striving 1065 (20.3) 50 (16.3)
Missing 736 (14.0) 39 (12.7)
TOTAL 5250 306Prescribing
Table 3 shows the average number of prescriptions per
patient, per year for inhaled b2 agonists, oral steroids
and antibiotics.Themost signi¢cantdi¡erence inmedica-
tionusage is in theuse of oral steroids.Childrenusing the
BAIwereprescribed 88% less oral steroids (Po0.05) and
adults 51.2% less (Po0.05) than thoseusingMDIs.There is
a large di¡erence (68%) in the average number of anti-
biotic prescriptions received by children using the BAI
compared to children using an MDI (Po0.05).The num-
ber of b2 agonist prescriptions for children using the BAI
is also signi¢cantly less than the number required for
children using an MDI (18%, P=0.036). All other mea-
sured medication variables show a non-signi¢cant trend
towards fewer prescriptions for BAI patients.
The average number of inhalers/tablets per script for
BAI users compared to MDI users is similar (Table 4).
Other resource use
Other determinants of asthma control in this analysis
areGPconsultations for both asthma and respiratory in-
fections, outpatient appointments and hospital admis-
sions (Table 3).
Themost signi¢cantdi¡erence inresourceuse for chil-
dren is in the amount of GP consultations for upper and
lower respiratory infections. Children using the BAI re-
quired 35.2% less of these than children using the MDI
(P=0.001). Adults and children using the BAI also re-
quired signi¢cantly fewer GP consultations for asthma
than MDI users (30.3% and 22.9%, respectively
(Po0.05)). All other measured resource-use variables
show a non-signi¢cant trend towards BAI patients using
less, with the exception of children using the BAI, who
required more outpatient appointments than children
using an MDI. The numbers of hospital admissions were
too small for percentage comparison, although overall
the trend for fewer of these with the BAI was still evi-
dent.
The existing patient data (i.e. those patients who
switched from one MDI to another or alternatively
switched from an MDI to the Easi-Breathes BAI at the
beginning of the study period) con¢rm the new patient
results (i.e. patients prescribed the BAI used less relief
medication and other clinical resources than those pre-
scribed anMDI).These data are to be reported in a sepa-
rate study.
Additional subgroup analysis
The average age of children using an MDI is lower than
for children using the BAI (5 years vs. 9 years). Further
investigation showed that younger children (0^5 years)
required more prescriptions for relief medication and
have more resource use (GP visits for asthma,GP visits
TABLE 3. Medication and resource usage, MDI users compared with BAI (Easi-Breathes) users (prescriptions or visits per
patient, per year)
BAI MDI Variation
Children Adults Children Adults Children Adults
n= 61 n= 245 n= 1585 n= 3665
Mean b2 agonists rx
per patient (95% CI)
1.869 2.784 2.276 3.127 0.41,18% 0.34,10.9%
(1.505,2.232) (2.357,3.211) (2.162,2.390) (3.001,3.253) P= 0.036 P= 0.179
Mean oral steroid rx
per patient (95% CI)
0.033 0.122 0.250 0.254 0.22,88% 0.13,51.2%
(0.013,0.079) (0.073,0.172) (0.218,0.282) (0.219,0.289) Po0.05 Po00.05
Mean antibiotic rx per
patient (95% CI)
0.131 0.253 0.412 0.308 0.28,68.0% 0.06,19.5%
(0.032,0.230) (0.177,0.329) (0.365,0.459) (0.283,0.334) Po0.05 P= 0.276
Mean GP consultations
for asthma (95% CI)
1.770 1.951 2.544 2.529 0.77,30.3% 0.58,22.9%
(1.375,2.166) (1.732,2.170) (2.431,2.657) (2.445,2.612) Po0.05 Po0.05
Mean GP consultations
for upper and lower
respiratory infection
(ULRI) (95% CI)
2.525 2.931 3.894 3.271 1.37,35.2% 0.34,10.4%
(1.802,3.247) (2.468,3.393) (3.688,4.100) (3.129,3.413) P= 0.001 P= 0.236
Meanoutpatient
appointments (95% CI)
0.164
(0.006,0.334)
0.114
(0.012,0.240)
0.081
(0.050,0.112)
0.206
(0.174,0.238)
+0.08,+103%
P= 0.312
0.09,-43.7%
P= 0.166
,BAIusers had less; + = BAIusers hadmore.
TABLE 4. Average number of inhalers/tablets per pre-
scription,MDIusers vs.BAIusers
MDI BAI
Oral steroid tablets 20.4 18.4
Antibiotic tablets 41.2 37.4
b2 Agonist inhalers 1.4 1.3
Steroid inhalers 1.2 1.2
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than older children (6^12 years) using an MDI. Patient
numbers in the BAI younger children group were too
small to produce reliable comparisons with older chil-
dren.
To allow for any distortion of results caused by young-
er children, a comparison of BAIvs.MDI use in older chil-
dren only was performed (Table 5). Results show that
overall older children (6^12 years) using the BAI still ap-
pear to be better controlled than those using MDIs. Sig-
ni¢cantly less oral steroid prescriptions were required
by older children using the BAI compared to MDI users
(70.2%, P=0.005). All other measured variables show
a non-signi¢cant trend towards BAI patients using less,
with the exception of outpatient appointments, where
BAI patients havemore of these than MDI patients.
DISCUSSION
There is growing appreciation of the fact that patients
and clinicians exhibit di¡erent behaviour in ‘real-life’ set-tings than in clinical trials. The traditional placebo-con-
trolled randomised trial will always be viewed as the
‘gold standard’ evaluation of the basic clinical and phar-
macological e⁄cacy of a medical intervention, but the
results of such trialsmaynotbeuncritically extrapolated
to general patient populations. Clinical trials of asthma
interventions generally have rigid and demanding entry
criteria that include good technique with the inhaler de-
livery device studied, as well as speci¢ed levels of objec-
tive air£ow obstruction, variability and reversibility and
speci¢ed symptom levels. In addition, the protocols of
such trials demand excellent compliancewith prescribed
regimes and tight self-monitoring of air£ow obstruction
and symptoms. Few of the patients with asthma seen in
routine daily clinical practice wouldmeet these require-
ments, and consequently the results obtained from such
trials cannot automatically be extrapolated to every-day
real-world practice.
It has been convincingly demonstrated that in real-
world settings, adherencewith prescribed treatment re-
gimes, particularly with prophylactic medication such as
ICS, is variable and frequently very di¡erent from in-
tended andprescribed regimes. In real-life situations, un-
like randomisedplacebo-controlled trials, patients know
what medication they are supposed to be taking and
make a decision whether or not to adhere to such
regimes, so a¡ecting outcomes of care. Many will
have poor inhaler technique in spite of instruction. In
real-world situations, where adherence and inhaler tech-
nique areverydi¡erent from those levels achievedin clin-
ical trials, outcomes of care may be di¡erent. This may
have important consequences on clinical outcomes and
TABLE 5. BAI vs.MDIuse in olderchildren (6^12 years)
BAI
n= 54
MDI
n= 571
Variance
Mean b2 agonists rx per patient (95% CI) 1.796 2.175 0.38,17.4%
(1.443,2.150) (1.993,2.357) P= 0.060
Meanoral steroidrxper patient (95% CI) 0.037 0.124 -0.087,70.2%
(0.015,0.089) (0.093,0.156) P= 0.005
Mean antibiotic rx per patient (95% CI) 0.129 0.22 0.09,41.4%
(0.023,0.236) (0.172,0.269) P= 0.124
Mean GPconsultations for asthma (95% CI) 1.777 1.982 0.205,10.3%
(1.342,2.214) (1.843,2.122) P= 0.395
Mean GPconsultations for upper and lower respiratory infection 2.388 2.802 0.414,14.8%
(ULRI) (95% CI) (1.625,3.153) (2.526,3.078) P= 0.382
Meanoutpatient appointments (95% CI) 0.185 0.029 +0.156,+537.93%
(0.007,0.377) (0.011,0.049) P= 0.112
,BAIusers had less; +,BAIusers hadmore.
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comes.
Pragmatic data can be obtained fromvarious sources,
includingpragmatic randomised trials, such as open-label
studies with broad and inclusive entry criteria, and also
from retrospective surveys of large and representative
clinical databases. There now exists a number of high-
quality clinical and prescribing primary care databases in
the U.K., which may be utilised in clinical e¡ectiveness
surveys, and are used in this survey.Data obtained from
such sources have both advantages and disadvantages.
The advantages include size, as large numbers of patient
records can be rapidly accessed, and generalisability, as
by de¢nition real-world entry criteria aremet. Accurate
prescribing and health resource usage data may be ob-
tained from such sources.There are disadvantages inher-
ent in observational data, which include lack of precise
case de¢nition, and lack of control for placebo and re-
gression to the mean e¡ects. In a comparative observa-
tional study of this kind, however, these considerations
apply to both arms equally, and so do not detract from
observed di¡erences in outcome.
In this study, signi¢cant improvements are seen in out-
comes for patients with asthma needing to commence
inhaled corticosteroid treatment in those commenced
on BAIs above those commenced on MDIs. Consistent
trends to improved outcomes from BAIs are seen in pae-
diatric and adult patients, and these trends achieve sta-
tistical signi¢cance for important markers of asthma
control such as the number of courses of oral corticos-
teroidsused for asthma exacerbations and thenumberof
asthma-related GP consultations. These improvements
are particularly apparent in children prescribed BAIs,
who were prescribed less rescue medication and
fewer courses of antibiotics than those prescribed
MDIs, and who needed to see the doctor less. A consis-tent trend to improved outcomes of all categories is
seen in the BAI group, and it is also noted that a separate
analysis of existing asthma patients reports similar
¢ndings.
It is of crucial importance in a comparative survey of
this type that the compared groups are similar; if one
group had for example more severe asthma, then the
outcomes of care would not necessarily represent the
di¡ering therapeutic e¡ects of the interventions used.
As a relatively recently introduced device, it is possible
that the BAI may be selected by prescribers in di¡erent
patient groups andmay bemonitored with closer atten-
tion than more familiar devices. It may be expected, for
instance, that the newer device would be selected in pa-
tients with more di⁄cult asthma or other adverse char-
acteristics such as poor adherence or inhaler technique,
although these factor would be expected to bias im-
proved outcomes towards the MDI group. In this survey,
however, the demographic data on the patients pre-
scribed BAIs and MDIs are similar in all major points ex-
cept for the 0^5 year age group, and no other baseline
di¡erences in the two groups was apparent, while out-
comes favoured the BAI group. Patient numbers in the
BAI and MDI groups di¡er considerably in this analysis;
this is an accurate re£ection of inhaler prescribing in the
U.K. and is an unavoidable aspect of such pragmatic
studies.
BAIs arenotgenerally technically feasible or appropri-
ate in the 0^5-year-old age group, for whom MDIs and
spacers are the preferred delivery option. In addition, it
has become apparent that there are di¡erent pheno-
types of wheezing illness in pre-school children, and
many of the children prescribed inhaled medication at
this age may not go on to develop full asthma. A sub-
group analysis of the 6^12 year old paediatric subjects
was therefore performed to ensure that the trends
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group.This analysis con¢rmed that 6^12 year oldpatients
using the BAI have signi¢cantly less prescriptions for oral
steroids and a non-signi¢cant trend towards less pre-
scriptions for antibiotics and b2 agonists thanMDI users.
Therewas also a trend towards less GP consultations for
asthma and respiratory infections than patients of the
same age using an MDI. However, these older children
using the BAI had more outpatient appointments than
the MDI users in this age group.This may be a re£ection
of the fact that the BAI was prescribed for these older
children who required specialist attention because of
the severity of their asthma. Although the number of
children prescribed BAIs in this database was low (61 pa-
tients, 3%), the signi¢cant di¡erences in outcomes over
the group prescribed MDIs indicate therapeutic potential
for BAIs in a group inwhom they are littleused at present,
andpoints to a need for prospective evaluations.
These ¢ndings have important implications for clinical
practice. In a time of limitedhealth resources, the impor-
tance of cost e¡ective as well as clinically e¡ective treat-
ment is generally accepted. Such considerations are of
particular importance in a common disease principally
treated in the community such as asthma. As di¡erent
delivery systems are available for inhaled asthmamedica-
tion, the choice of device for a particular patientwill have
repercussions for the clinical outcomes for that patient
and for the costs of their care to the individual and to
the community.Current guidelines recognise that di¡er-
entdevice systems exist, butdo not specify which should
be used for which patient; generally the advice has been
to use the cheapest device compatible with good out-
comes of care. It is accepted however that direct pre-
scribing costs are not the major determinant of total
outcome costs for asthma, and the demonstration that
slightlymore expensive technologiesmayresult in better
outcomes may therefore point to more e⁄cient use of
limited resources. These ¢ndings point to the need for
further pragmatic evaluations of the clinical and eco-
nomic outcomes of theuse of di¡erent asthma therapeu-
tic options in real-world settings.
In this study a comparisonwasmade of the clinical and
economic consequences of choosingmanual-and breath-
actuated pressurised metred dose inhalers.Other deliv-
ery devices, such as DPIs, are however available for in-
haled therapy in asthma. These devices are generally
more expensive than MDIs or BAIs in terms of prescrib-
ing costs, and there is a need for further ‘real-world’ clin-
ical and economic evaluations to be performed
comparing these device to MDIs and BAIs in order to
provide clinicians andpolicymakerswith evidence for ra-
tional recommendations on the choice of inhaler device.
In summary, this study suggests that the improved
compliance and improved lung deposition of medication
associatedwith BAIsmayresult in clinically and econom-
ically important consequences in real-world practice.Acknowledgements
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